Market Cap 40.00B
Revenue (ttm) 2.31B
Net Income (ttm) -208.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.03%
Debt to Equity Ratio 0.05
Volume 1,274,200
Avg Vol 1,619,314
Day's Range N/A - N/A
Shares Out 143.22M
Stochastic %K 99%
Beta 1.51
Analysts Strong Sell
Price Target $262.00

Company Profile

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provi...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 980 9190
Address:
13011 McCallen Pass, Building A Suite 100, Austin, United States
Intelligent_investor_
Intelligent_investor_ Jul. 4 at 3:26 PM
$TEM My screener tells me Tempus AI is a buy. So I will be buying šŸ™‰ $GH $NTRA
0 Ā· Reply
Ftrade24
Ftrade24 Jul. 3 at 9:33 PM
Part 2: The Evidence Since you’re so "unbothered" that you’re still reading, here is the data you’re trying to ignore: The CLOVER trial presented at AACR 2026 showed a median 70% ctDNA reduction by week 2 and tumor shrinkage/stable disease in 68% of patients at week 8. That’s rapid biomarker activity in a refractory, hospice-level population that had already exhausted standard of care. Furthermore, a $30B leader like Natera ($NTRA) does not enter a strategic partnership to perform molecular residual disease (MRD) analysis for a company that has "no effect" on the tumor. If you want "weekly updates," go follow a meme stock; if you want clinical validation, look at the AACR data and our current institutional roster. Your desperation to derail this is becoming the most bullish indicator of all. šŸš€šŸ“ˆ $CYDY #Leronlimab (2/2)
1 Ā· Reply
forbiddenavocado
forbiddenavocado Jul. 2 at 11:46 PM
$NTRA is going to tank next week. Multiple lawsuits, do your research people
1 Ā· Reply
B2iDigital
B2iDigital Jul. 2 at 7:32 PM
Profitable as of Q3 2025, Precipio (Nasdaq: $PRPO ) has canceled its ATM facility to move away from the dilutive capital raises common among microcap companies. Precipio, Inc. (Nasdaq: PRPO) did something uncommon for a microcap diagnostics company: it turned profitable, hitting that mark in the third quarter of 2025 and canceling the at-the-market facility it once leaned on. CEO Ilan Danieli framed the shift for microcap investors as a deliberate move toward financial independence. Precipio is a B2i Digital Featured Company. See the company's profile at b2idigital.com/precipio-inc-1 and follow Precipio on X, LinkedIn, and Facebook. "One of the most important things for us as a company to achieve in 2025 was to become profitable," said Danieli. "A couple years ago we did a capital raise. It wasn't the prettiest one, and our team sat around and said, that's it, we're done, we're not doing anything more. We're going to become financially independent. And we did. So we are profitable as of Q3 of 2025." Elsewhere in the session, Danieli covered: • That Precipio canceled its at-the-market (ATM) facility, a signal to shareholders that it would stop the dilutive financing many microcaps rely on • How a cash-efficient model lets the company fund new products without raising another $5 million and diluting investors each time • Why he believes operating profitably at the company's current scale makes for an attractive long-term business model Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the problem of cancer misdiagnoses by developing diagnostic products and services designed to deliver greater accuracy, improved laboratory workflow, and better patient outcomes. Precipio develops, validates, and clinically uses these technologies in its laboratory before commercializing them as proprietary products for the global laboratory community. More information is at precipiodx.com. Investor inquiries: [email protected], +1-203-787-7888 Ext. 523. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: This post is informational only and is not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. $EXAS, $NTRA, $GH, $XBI
1 Ā· Reply
Ftrade24
Ftrade24 Jul. 2 at 6:30 PM
$CYDY (Continued from Part 1)Furthermore, these anonymous bashers completely forget that CytoDyn partnered directly with MD Anderson Cancer Center for pivotal TNBC pre-clinical work to define how leronlimab pairs with immune checkpoint inhibitors, alongside Weill Cornell running the Alzheimer’s trial. Management explicitly stated on the corporate call that they are aggressively setting up additional strategic partnerships—and we already saw the multi-billion-dollar validation with Natera ($NTRA) drop right on the heels of that call. The ultimate proof? Dr. Kasi explicitly stated that late-stage CLOVER patients were facing exactly two options: Hospice or this trial. Now, those hospice-bound patients feel so good they went back to working full-time, creating scheduling conflicts for clinic visits! 🤯🤣 Anonymous avatars vs. a 7-site national trial network, MD Anderson, Weill Cornell, and $30B Natera. Cooked! šŸš€šŸ“ˆ $CYDY #Leronlimab
2 Ā· Reply
Ftrade24
Ftrade24 Jul. 2 at 5:32 PM
$CYDY @Djjazzyjeff Dropping a weak "lol" after I post a 4-part masterclass completely incinerating your bear narrative is the ultimate white flag. 🤔🤣 Mazzy had to log into a burner account because there isn't a single factual leg left to stand on! Let's recap what you just completely surrendered to: 🧠 Alzheimer's: Crushed the "useless endpoints" lie. Elite giants like Weill Cornell don't risk their global reputations on garbage data. āŒ The Chemo Fallacy: Exposed the absurdity that chemo+bev magically starts working after a late-stage patient already progressed and failed it. āŒ FDA Line Reality: Vaporized the claim that FDA doesn't care about lines of therapy. They mandate matched historical controls—the exact reason Natera ($NTRA) is mapping their database for CytoDyn. When you get so thoroughly checkmated on oncology science that your only response is a sockpuppet chuckle, you are completely cooked. šŸš€šŸ“ˆ $CYDY #Leronlimab
4 Ā· Reply
Ftrade24
Ftrade24 Jul. 2 at 5:17 PM
$CYDY @mazzystar1 Saying the FDA doesn't care about the line of therapy or that CYDY has to beat bev+chemo in "ANY line" is a total regulatory hallucination. 🤔 Here is real FDA oncology reality: āŒ Line-Specific Approvals: The FDA strictly approves oncology drugs for specific lines of therapy. They judge 3rd/4th-line refractory drugs against 3rd/4th-line standard outcomes—NOT 1st-line. āŒ The Control Arm Fallacy: Mazzy thinks no control arm means line doesn't matter. Wrong. For single-arm oncology trials, the FDA requires comparison to a historical control of the exact same line & demographic. āŒ The Natera Reality: This is the exact point of the $NTRA partnership! Natera is using its massive database to map a matched historical control of 3rd/4th-line patients who failed chemo+bev to prove leronlimab's efficacy. Comparing 3rd-line data to 1st-line is a scientific joke. Learn how oncology approvals work. šŸš€ $CYDY #Leronlimab
0 Ā· Reply
Ftrade24
Ftrade24 Jul. 2 at 4:51 PM
The moving goalposts from $CYDY bashers are officially in outer space. šŸš€šŸ¤” 1ļøāƒ£ Before Natera: "The CLOVER mCRC data is totally fake, CytoDyn is fabricating those massive ~70% ctDNA drops!" 🤄 2ļøāƒ£ After Natera: "Okay, but ctDNA drops naturally happen anyway from Standard of Care!" 🤣 3ļøāƒ£ The Latest Coping Mechanism: "The FDA won't accept Phase 2 open-label data anyway!" šŸ“‰ Let's think about this logically. Why on earth would CytoDyn partner with a $30B global leader and precision-medicine powerhouse like Natera ($NTRA) if they were hiding fake results? If the data was "BS," handing it over to Natera’s Signatera platform to be cross-referenced against their massive oncology database would be corporate suicide. CytoDyn initiated this strategic collaboration because they know the data is bulletproof. (1/2) #Leronlimab
1 Ā· Reply
WAJeff
WAJeff Jul. 1 at 5:33 PM
$GH $NTRA Very strong
0 Ā· Reply
WAJeff
WAJeff Jul. 1 at 3:13 PM
$NTRA $279.42 ath before the fade
0 Ā· Reply
Latest News on NTRA
Natera price target raised to $290 from $270 at Guggenheim

2026-06-29T11:06:11.000Z - 5 days ago

Natera price target raised to $290 from $270 at Guggenheim


Natera, Aveta Biomics announce strategic partnership

2026-06-29T10:15:16.000Z - 5 days ago

Natera, Aveta Biomics announce strategic partnership


Natera resumed with an Outperform at Bernstein

2026-06-26T10:30:34.000Z - 8 days ago

Natera resumed with an Outperform at Bernstein


Natera, Eledon announce strategic partnership

2026-06-25T11:05:47.000Z - 9 days ago

Natera, Eledon announce strategic partnership

ELDN


Natera price target raised to $275 from $270 at BTIG

2026-06-24T17:05:16.000Z - 10 days ago

Natera price target raised to $275 from $270 at BTIG


Natera price target lowered to $260 from $280 at Barclays

2026-06-24T08:55:30.000Z - 10 days ago

Natera price target lowered to $260 from $280 at Barclays


NCCN recommends ctDNA-MRD testing using Signatera technology

2026-06-23T21:26:48.000Z - 11 days ago

NCCN recommends ctDNA-MRD testing using Signatera technology


Natera price target raised to $270 from $250 at BTIG

2026-06-23T21:20:11.000Z - 11 days ago

Natera price target raised to $270 from $250 at BTIG


Natera resumed with an Outperform at RBC Capital

2026-06-11T20:15:54.000Z - 23 days ago

Natera resumed with an Outperform at RBC Capital


Natera Transcript: AGM 2026

Jun 11, 2026, 2:30 PM EDT - 23 days ago

Natera Transcript: AGM 2026


Natera initiated with a Neutral at Goldman Sachs

2026-06-05T08:35:07.000Z - 4 weeks ago

Natera initiated with a Neutral at Goldman Sachs


Natera appoints Lynch, Rubin to board of directors

2026-06-03T13:15:42.000Z - 4 weeks ago

Natera appoints Lynch, Rubin to board of directors


Natera assumed with an Outperform at Wolfe Research

2026-06-01T20:52:08.000Z - 4 weeks ago

Natera assumed with an Outperform at Wolfe Research


Natera enrolls first patients in SIGNAL-ER 101 study

2026-05-28T10:25:18.000Z - 5 weeks ago

Natera enrolls first patients in SIGNAL-ER 101 study


The Cancer Test That Wall Street Is Betting On

May 14, 2026, 5:30 AM EDT - 7 weeks ago

The Cancer Test That Wall Street Is Betting On


AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

May 10, 2026, 2:30 PM EDT - 7 weeks ago

AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth

EW ISRG LLY NVO


Natera Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Natera Earnings Call Transcript: Q1 2026


Natera Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Natera Slides: Q1 2026


Natera Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Natera Earnings release: Q1 2026


Natera Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 2 months ago

Natera Quarterly report: Q1 2026


Natera Reports First Quarter 2026 Financial Results

May 7, 2026, 4:05 PM EDT - 2 months ago

Natera Reports First Quarter 2026 Financial Results


Natera to Report its First Quarter Results on May 7, 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Natera to Report its First Quarter Results on May 7, 2026


Natera Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Natera Proxy statement: Proxy filing


Natera Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Natera Proxy statement: Proxy filing


Natera Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 8:00 AM EDT - 4 months ago

Natera Transcript: Leerink Global Healthcare Conference 2026


Natera Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Natera Earnings Call Transcript: Q4 2025


Natera Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Natera Annual report: Q4 2025


Natera Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Natera Earnings release: Q4 2025


Natera Slides: Q4 2025

Feb 26, 2026, 4:30 PM EST - 4 months ago

Natera Slides: Q4 2025


Natera Submits Signateraā„¢ CDx PMA to FDA

Feb 2, 2026, 6:00 AM EST - 5 months ago

Natera Submits Signateraā„¢ CDx PMA to FDA


Natera Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 PM EST - 6 months ago

Natera Transcript: 44th Annual J.P. Morgan Healthcare Conference


Natera Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 PM EST - 6 months ago

Natera Slides: 44th Annual J.P. Morgan Healthcare Conference


Intelligent_investor_
Intelligent_investor_ Jul. 4 at 3:26 PM
$TEM My screener tells me Tempus AI is a buy. So I will be buying šŸ™‰ $GH $NTRA
0 Ā· Reply
Ftrade24
Ftrade24 Jul. 3 at 9:33 PM
Part 2: The Evidence Since you’re so "unbothered" that you’re still reading, here is the data you’re trying to ignore: The CLOVER trial presented at AACR 2026 showed a median 70% ctDNA reduction by week 2 and tumor shrinkage/stable disease in 68% of patients at week 8. That’s rapid biomarker activity in a refractory, hospice-level population that had already exhausted standard of care. Furthermore, a $30B leader like Natera ($NTRA) does not enter a strategic partnership to perform molecular residual disease (MRD) analysis for a company that has "no effect" on the tumor. If you want "weekly updates," go follow a meme stock; if you want clinical validation, look at the AACR data and our current institutional roster. Your desperation to derail this is becoming the most bullish indicator of all. šŸš€šŸ“ˆ $CYDY #Leronlimab (2/2)
1 Ā· Reply
forbiddenavocado
forbiddenavocado Jul. 2 at 11:46 PM
$NTRA is going to tank next week. Multiple lawsuits, do your research people
1 Ā· Reply
B2iDigital
B2iDigital Jul. 2 at 7:32 PM
Profitable as of Q3 2025, Precipio (Nasdaq: $PRPO ) has canceled its ATM facility to move away from the dilutive capital raises common among microcap companies. Precipio, Inc. (Nasdaq: PRPO) did something uncommon for a microcap diagnostics company: it turned profitable, hitting that mark in the third quarter of 2025 and canceling the at-the-market facility it once leaned on. CEO Ilan Danieli framed the shift for microcap investors as a deliberate move toward financial independence. Precipio is a B2i Digital Featured Company. See the company's profile at b2idigital.com/precipio-inc-1 and follow Precipio on X, LinkedIn, and Facebook. "One of the most important things for us as a company to achieve in 2025 was to become profitable," said Danieli. "A couple years ago we did a capital raise. It wasn't the prettiest one, and our team sat around and said, that's it, we're done, we're not doing anything more. We're going to become financially independent. And we did. So we are profitable as of Q3 of 2025." Elsewhere in the session, Danieli covered: • That Precipio canceled its at-the-market (ATM) facility, a signal to shareholders that it would stop the dilutive financing many microcaps rely on • How a cash-efficient model lets the company fund new products without raising another $5 million and diluting investors each time • Why he believes operating profitably at the company's current scale makes for an attractive long-term business model Precipio is a healthcare biotechnology company focused on cancer diagnostics. Its mission is to address the problem of cancer misdiagnoses by developing diagnostic products and services designed to deliver greater accuracy, improved laboratory workflow, and better patient outcomes. Precipio develops, validates, and clinically uses these technologies in its laboratory before commercializing them as proprietary products for the global laboratory community. More information is at precipiodx.com. Investor inquiries: [email protected], +1-203-787-7888 Ext. 523. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: This post is informational only and is not an offer or solicitation regarding any security. See the complete Disclosure at b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. $EXAS, $NTRA, $GH, $XBI
1 Ā· Reply
Ftrade24
Ftrade24 Jul. 2 at 6:30 PM
$CYDY (Continued from Part 1)Furthermore, these anonymous bashers completely forget that CytoDyn partnered directly with MD Anderson Cancer Center for pivotal TNBC pre-clinical work to define how leronlimab pairs with immune checkpoint inhibitors, alongside Weill Cornell running the Alzheimer’s trial. Management explicitly stated on the corporate call that they are aggressively setting up additional strategic partnerships—and we already saw the multi-billion-dollar validation with Natera ($NTRA) drop right on the heels of that call. The ultimate proof? Dr. Kasi explicitly stated that late-stage CLOVER patients were facing exactly two options: Hospice or this trial. Now, those hospice-bound patients feel so good they went back to working full-time, creating scheduling conflicts for clinic visits! 🤯🤣 Anonymous avatars vs. a 7-site national trial network, MD Anderson, Weill Cornell, and $30B Natera. Cooked! šŸš€šŸ“ˆ $CYDY #Leronlimab
2 Ā· Reply
Ftrade24
Ftrade24 Jul. 2 at 5:32 PM
$CYDY @Djjazzyjeff Dropping a weak "lol" after I post a 4-part masterclass completely incinerating your bear narrative is the ultimate white flag. 🤔🤣 Mazzy had to log into a burner account because there isn't a single factual leg left to stand on! Let's recap what you just completely surrendered to: 🧠 Alzheimer's: Crushed the "useless endpoints" lie. Elite giants like Weill Cornell don't risk their global reputations on garbage data. āŒ The Chemo Fallacy: Exposed the absurdity that chemo+bev magically starts working after a late-stage patient already progressed and failed it. āŒ FDA Line Reality: Vaporized the claim that FDA doesn't care about lines of therapy. They mandate matched historical controls—the exact reason Natera ($NTRA) is mapping their database for CytoDyn. When you get so thoroughly checkmated on oncology science that your only response is a sockpuppet chuckle, you are completely cooked. šŸš€šŸ“ˆ $CYDY #Leronlimab
4 Ā· Reply
Ftrade24
Ftrade24 Jul. 2 at 5:17 PM
$CYDY @mazzystar1 Saying the FDA doesn't care about the line of therapy or that CYDY has to beat bev+chemo in "ANY line" is a total regulatory hallucination. 🤔 Here is real FDA oncology reality: āŒ Line-Specific Approvals: The FDA strictly approves oncology drugs for specific lines of therapy. They judge 3rd/4th-line refractory drugs against 3rd/4th-line standard outcomes—NOT 1st-line. āŒ The Control Arm Fallacy: Mazzy thinks no control arm means line doesn't matter. Wrong. For single-arm oncology trials, the FDA requires comparison to a historical control of the exact same line & demographic. āŒ The Natera Reality: This is the exact point of the $NTRA partnership! Natera is using its massive database to map a matched historical control of 3rd/4th-line patients who failed chemo+bev to prove leronlimab's efficacy. Comparing 3rd-line data to 1st-line is a scientific joke. Learn how oncology approvals work. šŸš€ $CYDY #Leronlimab
0 Ā· Reply
Ftrade24
Ftrade24 Jul. 2 at 4:51 PM
The moving goalposts from $CYDY bashers are officially in outer space. šŸš€šŸ¤” 1ļøāƒ£ Before Natera: "The CLOVER mCRC data is totally fake, CytoDyn is fabricating those massive ~70% ctDNA drops!" 🤄 2ļøāƒ£ After Natera: "Okay, but ctDNA drops naturally happen anyway from Standard of Care!" 🤣 3ļøāƒ£ The Latest Coping Mechanism: "The FDA won't accept Phase 2 open-label data anyway!" šŸ“‰ Let's think about this logically. Why on earth would CytoDyn partner with a $30B global leader and precision-medicine powerhouse like Natera ($NTRA) if they were hiding fake results? If the data was "BS," handing it over to Natera’s Signatera platform to be cross-referenced against their massive oncology database would be corporate suicide. CytoDyn initiated this strategic collaboration because they know the data is bulletproof. (1/2) #Leronlimab
1 Ā· Reply
WAJeff
WAJeff Jul. 1 at 5:33 PM
$GH $NTRA Very strong
0 Ā· Reply
WAJeff
WAJeff Jul. 1 at 3:13 PM
$NTRA $279.42 ath before the fade
0 Ā· Reply
Penny_stock_Raid_Boss
Penny_stock_Raid_Boss Jun. 30 at 3:44 PM
$ELDN $NTRA current price 2.45? Wtf drunk bot is drunk.
0 Ā· Reply
BarbaraSmith247
BarbaraSmith247 Jun. 30 at 1:43 PM
$ELDN current price 2.45. The announcement of a partnership with $NTRA for the use of the Prospera test in the upcoming Phase 3 trial for tegoprubart provides a clear data-driven roadmap. Market focus remains on the scale of global patient enrollment starting later this year. Balance sheet and cash runway remain the primary variables for long-term holders.
0 Ā· Reply
Serranito
Serranito Jun. 29 at 8:39 PM
Technical Analysis of $NTRA https://onlytradersfans.com/threads/analisis-tecnico-natera.11976/ Remember that investing involves risks, and it's important that you do your own research. Let's learn and grow together!
0 Ā· Reply
YushimiCloud
YushimiCloud Jun. 29 at 8:01 PM
$NTRA so far so good
0 Ā· Reply
WAJeff
WAJeff Jun. 29 at 7:39 PM
$NTRA 6/4 221.38s sold $272.93, great month here. Still have half my position going for $300
1 Ā· Reply
MonkeyBananaGenius
MonkeyBananaGenius Jun. 29 at 7:08 PM
$NTRA trimmed some for 80% gains
0 Ā· Reply
bellaboos
bellaboos Jun. 29 at 4:19 PM
$NTRA + CYDY = SUCCESS !!!
0 Ā· Reply
WAJeff
WAJeff Jun. 29 at 2:43 PM
$NTRA $274.47 ath
0 Ā· Reply
Estimize
Estimize Jun. 29 at 11:03 AM
Wall St is expecting -0.49 EPS for $NTRA Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/ntra?chart=historical&metric_name=eps&utm_c
0 Ā· Reply
BioTechHealthX
BioTechHealthX Jun. 28 at 7:12 AM
$NTRA Natera, Inc. (NTRA) avoided a major damages overhang after the U.S. Supreme Court declined to hear CareDx’s appeal. With 68 hedge fund holders, strong genetic testing exposure, and a role in data-driven healthcare, this precision medicine stock is getting harder to ignore. https://biotechhealthx.com/biotech-news/heres-why-natera-ntra-could-be-a-big-winner-in-precision-medicine/
0 Ā· Reply
BioTechHealthX
BioTechHealthX Jun. 28 at 6:10 AM
$DXCM $GEHC $INSM $NTRA $VEEV From obesity drugs and genetic testing to glucose biosensors, cloud imaging, and surgical tools, these 10 AI healthcare stocks show how artificial intelligence is reshaping patient care, diagnostics, drug research, and medical technology. https://biotechhealthx.com/biotech-news/top-10-ai-powered-healthcare-stocks-that-can-make-you-rich/
0 Ā· Reply
arribaStocktrading
arribaStocktrading Jun. 26 at 7:54 PM
$PSNL We have the Magnificent 4 now: $GH $NTRA $PSNL (of course) and $ADPT All 4 have made new 52-week highs either yesterday or today!
1 Ā· Reply